Lifescience Dynamics Limited

Expanding the VISTA for obesity: A portfolio-driven approach At #ObesityWeek2024, AstraZeneca unveiled first-in-human data for three anti-obesity drug candidates, including AZD5004 (glucagon-like peptide 1 receptor agonist; GLP-1RA), AZD6234 (dual amylin/calcitonin receptor agonist), and AZD9550 (dual GLP-1/glucagon receptor agonist). With over 1 billion individuals now struggling with obesity, the market is primed to receive new and innovative therapies that can reduce the global burden of obesity and related diseases. In Phase 1 evaluation, the company’s oral candidate, AZD5004, yielded a mean body weight reduction of approximately 2% (placebo-adjusted) after 16-weeks of treatment in ten patients titrated up to the highest dose. While not an improvement versus other oral GLP-1RAs (orforglipron, Eli Lilly; GSBR-1290, Structure Therapeutics), early data suggests potential differentiation in drug tolerability. As GI-related side effects remain a key challenge to the GLP-1RA class, the fact AZD5004 had discontinuation rates of 4% despite three of four MAD cohorts proceeding without dose titration is noteworthy. Aside of the data presented, AstraZeneca’s portfolio-driven approach to entering the obesity market is framed by plans to initiate trials for novel combinations to broadly address cardiometabolic health, while also turning an eye to the future with emerging mechanisms of action. In pursuit of this goal, AstraZeneca has now initiated Phase 2b trials for AZD5004 (VISTA, SOLSTICE) and AZD6234 (APRICUS), while a Phase 1/2 trial for AZD9550 (CONTEMPO) remains ongoing. Additionally, with initial safety data for AZD9550 showing mild-to-moderate GI side effects, and single-doses of AZD6234 yielding up to 3.8% weight loss, the company is actively planning a Phase 2b trial to evaluate AZD6234 in combination with AZD9550. In 2024 and beyond, competitors are increasingly looking to combinations therapies to meet unmet needs, including muscle-mass preservation during weight loss, and providing therapeutic options for patients with suboptimal responses to GLP-1RAs. For more information, contact María González-Gancedo del Hoyo, Chris Onderisin, Austin Jeffries, or Kyasha Sri Ranjan #AstraZeneca #NovoNordisk #EliLilly #Amgen #StructureTherapeutics #VikingTherapeutics #Roche #Regeneron #ObesityWeek2024 #AZD5004 #AZD6234 #AZD9550 #Obesity #Diabetes #LifescienceDynamics

Since their launch, CAR-T therapies have remained entrenched in uncertainties around their efficacy and safety. Over time, real-world data has aided in easing this uncertainty, which may drive significant changes in how CAR-T therapies are reimbursed. Join us at ISPOR, Europe to discuss how real-world data may drive the evolution of CAR-T reimbursement (19th November 2024, 3.15pm CET).  #ISPOREurope #LifescienceDynamics #ISPOR #ISPOR2024 #pharma #biotech #CAR_T #Immunotherapy

On Remembrance Day we are proud to commemorate those who gave their lives for our freedom during the First World War, and during all conflicts before and since.   We must also remember those who are currently living without these freedoms, and those who continue to give their lives for a more peaceful world.   Today, we will fall silent at 11am and remember them.

Will you be attending ISPOR, Europe? The Lifescience Dynamics’ team will be heading to Barcelona next week and are looking forward to connecting with clients, peers and friends in person. Be sure to stop by our stand (no.1327), or feel free to message Alberto Briones, PhD to arrange a meeting! We look forward to seeing you there. #ISPOREurope #LifescienceDynamics #ISPOR #ISPOR2024 #pharma #biotech

To all our clients, colleagues and friends celebrating Diwali, we wish you a wonderful time during the Festival of Lights. The message of Diwali remains as important as ever – we must always celebrate what is good, bright and hopeful in the world. We hope that you are able to spend this time with family and friends, and relish in the joy and prosperity of the season! #diwali2024 #diwalifestival #diwalicelebration

Lifescience Dynamics wishes you a spoooooky Halloween! Hoping you receive more treats than tricks today, and enjoy the spook-tacular celebrations! It's time to boo-gie! #Halloween #LifescienceDynamics #boo #sqaudghouls #spookyseason

As October draws to a close, so does this year’s Black History Month. A month which provides the opportunity to spotlight and celebrate the achievements, culture and history of Black people. This year’s theme for Black History Month is ‘Reclaiming Narratives’. By focussing on recognition and correction within Black history and culture, this theme marks a powerful shift in how we celebrate and view these accounts and experiences. When conducting a cursory Google of ‘great scientists’, you are met with a deluge of famous faces – including, but not exclusive to, the likes of Newton, Darwin, Einstein and Curie. Delve a little deeper and you will discover some articles titled, ‘The Greatest Scientists of all Time’ which fail to include a single Black scientist (or any scientist of colour for that matter). While the notion of ranking figures through history is generally arbitrary, this absence risks giving the false impression that the discipline of science has been pioneered solely by White people. This is not the case. We would like to take this moment to bring attention to some of the many brilliant Black scientists who have shaped the field. Mary Seacole, a nurse and businesswoman who, during the Crimean War, established ‘The British Hotel’, a hospital right behind the front lines between Balaklava and Sevastopol. Despite returning to England as famous as Florence Nightingale post-war, Mary’s story was all but forgotten after her death until a group of Jamaican nurses rediscovered her in the 1980s. Dr Daniel Hale Williams, the physician credited with the first successful heart surgery and founder of America’s first interracial hospital in 1891. Percy Lavon Julian, a chemist and pioneer in chemical synthesis of medicinal drugs from plants. His biomedical research made it possible to produce industrial large-scale quantities of synthetic hormones, still used in medical treatments today. Dame Elizabeth Anionwu, the UK’s first sickle-cell and thalassemia nurse specialist. Anionwu helped establish the ‘Brent Sickle Cell and Thalassaemia Counselling Centre’, a trailblazing service which led to the nationwide screening of babies. It would be errant to overlook the adversity and discrimination faced by each of these individuals when sharing their stories. On top of their careers and contributions to science, they are all known for partaking in some level of activism in order to better the prospects and possibilities for others. Lifescience Dynamics has and continues to be inspired by the incredible, innovative work of Black scientists, whose contributions and discoveries shape our industry to this day. #BlackHistoryMonth #ReclaimingNarratives #LifescienceDynamics More on Mary Seacole: https://shorturl.at/TCYst More on Dr Daniel Hale Williams: https://shorturl.at/UkGo2 More on Percy Lavon Julian: https://shorturl.at/4yt3F More on Dame Elizabeth Anionwu: https://shorturl.at/a8Fnf

Women’s Health is making the shift towards more individualised treatment. Options are expanding and becoming more available, as seen with the recent acceptance of NDA submissions for Bayer's non-hormonal menopause therapy, Elinzanetant, that has followed the approval of Astellas' Veozah. These ground-breaking non-hormonal options offer hope for women suffering from the symptoms of menopause (eg. hot flushes and night sweats). Those that may be at risk of adverse events, such as risk of breast cancer associated with hormone replacement therapy, now have alternative avenues to explore. With companies like Pfizer also relaunching HRT assets and others such as Mithra and Dare developing differentiated hormonal assets, the menopause care landscape is rapidly evolving. This new attention to the care and management of menopause represents not only a market opportunity, but a cultural shift toward education and empowerment in women’s health. The increase in available treatment options to manage women’s health signals an important step towards recognition of their needs in the pharmaceutical landscape.  Read more at: https://shorturl.at/9AwDd #LifesicenceDynamics #WomensHealth #nonhormonal #menopausetherapy #menopause Bayer Astellas Pharma

Day 1 of Pharma CiMiCON is complete ✔️ Join us tomorrow from 11:30am onward where Paola Hentges Pinto, PhD and Matt Stebbings will be leading our round table (world cafe) session. Do be sure to stop by to gain some valuable insights into emerging markets. The rest of the team will also be located at booth 1 through the day, ready to meet with you and answer any questions. #CiMiCON #PharmaCiMiCON #LifescienceDynamics CIMICON Event Series

Are you interested in learning how to improve your workshops? Come along to our Plenary Talk at Pharma CiMiCON, Berlin where Matt Stebbings will be exploring how industry experience can shape workshop efficacy. The session begins at 9:00am on Monday October 7th, what a great start to the week!  #CiMiCON #PharmaCiMiCON #LifescienceDynamics